Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Arch Iran Med. 2022 Sep 1;25(9):609-616. doi: 10.34172/aim.2022.96.
Breast cancer survival rate is an important index for assessment of treatment effect in reducing the mortality. Weaimed to determine the fifteen-year survival rate for breast cancer at a referral center in Iran and its correlated factors.
This survival study enrolled patients with breast cancer who referred to Motamed Cancer Institute (MCI) from 1998 to2016. The survival rate was calculated using the Kaplan-Meier method. The relationship of demographic, clinical and therapeuticfactors with overall survival (OS) was studied using Cox's proportional hazard model.
Totally, 3443 patients were studied. Their mean age and follow-up period were 47.7 (±11.43) years and 61.66 (±52.1)months, respectively. The median follow-up time was 48.4 months (range: 1-413 months), 49.7% of the patients had high schoolor higher education, and 71.3% presented in the early stage of the disease. Death occurred in 505 (14.7%) of the patients. Theoverall 2-, 5-, 7-, 10- and 15-year survival rates were 93%, 82%, 78%, 74%, and 66%, respectively. Lymph node involvement(HR=2.07; 95% CI: 1.38-3.09), tumor size≥5 cm (HR=2.83; 95% CI: 1.59-2.04), being single/divorced/widowed (HR=1.65;95% CI: 1.13-2.4), and education level<high school diploma (HR=1.57; 95% CI: 1.13-2.17) were independent predictors ofbreast cancer survival.
The five-year breast cancer survival rate in this study was higher than reported by some other studies in Iran, whichcould be due to the multidisciplinary treatment approach in MCI. Tumor size and lymph node involvement as indicators ofdelayed diagnosis may affect breast cancer survival, even though their true effect due to lead-time bias should be considered. Thecorrelation of education level with survival confirms the importance of awareness and the need to establish strategies for earlydiagnosis in Iranian women.
乳腺癌存活率是评估治疗效果降低死亡率的一个重要指标。我们旨在确定伊朗某转诊中心的乳腺癌十五年存活率及其相关因素。
本生存研究纳入了 1998 年至 2016 年间向 Motamed 癌症研究所(MCI)转诊的乳腺癌患者。采用 Kaplan-Meier 法计算生存率。使用 Cox 比例风险模型研究人口统计学、临床和治疗因素与总生存(OS)的关系。
共纳入 3443 例患者。他们的平均年龄和随访时间分别为 47.7(±11.43)岁和 61.66(±52.1)个月。中位随访时间为 48.4 个月(范围:1-413 个月),49.7%的患者受过高中或以上教育,71.3%的患者处于疾病早期。505 例(14.7%)患者死亡。总体 2、5、7、10 和 15 年生存率分别为 93%、82%、78%、74%和 66%。淋巴结受累(HR=2.07;95%CI:1.38-3.09)、肿瘤大小≥5 cm(HR=2.83;95%CI:1.59-2.04)、单身/离异/丧偶(HR=1.65;95%CI:1.13-2.4)和受教育程度<高中文凭(HR=1.57;95%CI:1.13-2.17)是乳腺癌生存的独立预测因素。
本研究五年乳腺癌存活率高于伊朗其他一些研究报告,这可能是由于 MCI 采用了多学科治疗方法。肿瘤大小和淋巴结受累作为延迟诊断的指标可能会影响乳腺癌的生存,尽管由于领先时间偏倚,其真正的影响应该被考虑。教育程度与生存的相关性证实了提高认识的重要性,并需要为伊朗女性制定早期诊断策略。